SHIJIAZHUANG NO.4 PHARMACEUTICAL CO., LTD
Shijiazhuang No.4 Pharmaceutical Co Ltd is a large-sized civilian-run public share holding and comprehensive medicine manufacturer in China, with the capacity of manufacturing 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc. For the key product of large volume I.V solution, there are 6 GMP approved production lines with the yearly capacity of more than 150 million bottles in the dosage of 500 ml/ 250 ml /100ml. Both variety of the products and yearly output are in the leading position of this field in China.
To meet the global pharmaceutical market, the company has put a large amount of investment into the development of new medicines and techniques innovation. The I.V solution products and Chinese Traditional Herb medicines have become the 250 million main development directions of the company. In the latest years, Anti-brain Recession capsule, SHANHE oral liquid, Pentoxifylline and Sodium Chloride Injection, Inosine and Glucose Injection and Azithromycin Injection have put into market and get the consumers recognition.
The company insists on the ideal of Quality first and human health uppermost and has established the three-grade quality assurance system. The company operates under the GMP standard for the production and management to assure the whole production procedure supervised and the quality of the products. In recent ten years, the rate of qualified market samples is 100% inspected & tested by the National Pharmaceutical Supervision and Management Administration. By the end of 2001, all of the production of the products such as infusions, capsules, granules, tablets and etc. are GMP approved by China National Pharmaceutical Supervision and Management Administration. All for the satisfactory of the customers is our basic principle of sales work.
With the flexible sales manner and good after-sales service, we have set up a sales network in Beijing, Tianjin and North China as the center, and Wuhan, Shanghai, Chongqing, Guangdong, Shenzhen, Zhejiang and etc as the radiation area. Looking forward to the 21tst century, we will go on developing our management and production techniques to meet the market and realize a big leap.
|Sales markets||Africa; Asia; Australia; Central/South America; Eastern Europe; Middle East; North America; Western Europe|
|Primary business activity||Contract Manufacturer|